GlassScriptPhysician profile
Frances Eleanor Lafferty
NPI 1962930891
$3,244.90
in general payments reported to CMS, 2019-2025
33 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $233 · 2021: $518 · 2022: $260 · 2023: $653 · 2024: $755 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $484.77 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $441.62 | 2021-2025 | |
| Novo Nordisk INC | $326.49 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $206.57 | 2020-2025 | Airsupra, Farxiga, Breztri |
| Viiv Healthcare Company | $183.78 | 2024-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.01 | 2020-2024 | Jardiance |
| Amgen INC. | $160.69 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $158.88 | 2023-2025 | |
| Corium, LLC | $121.00 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $104.49 | 2020-2024 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $100.99 | 2020-2021 | |
| Amarin Pharma, INC. | $86.08 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.76 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $70.84 | 2021-2024 | Livalo, Zoryve |
| Novartis Pharmaceuticals Corporation | $68.47 | 2023-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $55.51 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.86 | 2020-2024 | Xifaxan |
| Grifols USA, LLC | $37.63 | 2024 | Xembify |
| Abbott Laboratories | $35.71 | 2021-2025 | Freestyle Libre 3 |
| Radius Health, INC. | $32.11 | 2025 | Tymlos |
| Exact Sciences Corporation | $29.04 | 2024 | Cologuard Collection Kit |
| Neurelis, INC. | $24.65 | 2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $24.21 | 2025 | Strensiq |
| Boston Scientific Corporation | $23.80 | 2025 | Watchman Flx |
| Ardelyx, INC. | $21.77 | 2025 | Ibsrela |
| Scilex Pharmaceuticals INC. | $21.40 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $20.55 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $20.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $17.90 | 2024 | Quviviq |
| Esperion Therapeutics, INC. | $17.87 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $15.54 | 2022 | |
| Eisai INC. | $14.68 | 2021 | |
| Ironwood Pharmaceuticals, INC | $13.87 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frances Lafferty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.